Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 558 entries
Sorted by: Best Match Show Resources per page
The effect of ursodeoxycholic acid therapy on gallstone formation in the morbidly obese during rapid weight loss

program design

[No authors listed]
GSID: a_1LPUiJ8iwJ
LJ Worobetz, FG Inglis… - American Journal of …, 1993 - search.ebscohost.com

Obesity is a significant risk factor for cholesterol gallstone formation, particularly when patients are morbidly obese and rapidly losing weight. Our objective, in a double-blind …

Cite
Worobetz, L. J., Inglis, F. G., & Shaffer, E. A. (1993). The effect of ursodeoxycholic acid therapy on gallstone formation in the morbidly obese during rapid weight loss. American Journal of Gastroenterology (Springer Nature), 88(10).
Worobetz, L. J., F. G. Inglis, and E. A. Shaffer. "The effect of ursodeoxycholic acid therapy on gallstone formation in the morbidly obese during rapid weight loss." American Journal of Gastroenterology (Springer Nature) 88.10 (1993).
Copy Download .nbib Format: MLA
Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program

program design

[No authors listed]
GSID: 8k6QPLW2N3EJ
ML Shiffman, GD Kaplan… - Annals of internal …, 1995 - acpjournals.org

… program longer and lost more weight, on average, than patients who did develop gallstones. Because measurements of absolute weight loss were biased by this study design… term follow-up after patients completed the diet program and ursodeoxycholic acid prophylaxis....

Cite
Shiffman, M. L., Kaplan, G. D., Brinkman-Kaplan, V., & Vickers*, F. F. (1995). Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program. Annals of internal medicine, 122(12), 899-905.
Shiffman, Mitchell L., et al. "Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program." Annals of internal medicine 122.12 (1995): 899-905.
Copy Download .nbib Format: MLA
Urinary bile acid sulfate levels in patients with primary biliary cirrhosis.

Hepatology research : the official journal of the Japan Society of Hepatology

Miura R, Tanaka A, Takikawa H.
PMID: 21348908
Hepatol Res. 2011 Apr;41(4):358-63. doi: 10.1111/j.1872-034X.2011.00779.x. Epub 2011 Feb 23.

AIM:   Urinary bile acids are mainly conjugated with sulfuric acid. In a previous work, we demonstrated that the levels of urinary sulfated bile acids (USBA) and serum total bile acids (TBA) were correlated very well and also that USBA...

Cite
Miura R, Tanaka A, Takikawa H. Urinary bile acid sulfate levels in patients with primary biliary cirrhosis. Hepatol Res. 2011;41(4):358-63doi: 10.1111/j.1872-034X.2011.00779.x.
Miura, R., Tanaka, A., & Takikawa, H. (2011). Urinary bile acid sulfate levels in patients with primary biliary cirrhosis. Hepatology research : the official journal of the Japan Society of Hepatology, 41(4), 358-63. https://doi.org/10.1111/j.1872-034X.2011.00779.x
Miura, Ryo, et al. "Urinary bile acid sulfate levels in patients with primary biliary cirrhosis." Hepatology research : the official journal of the Japan Society of Hepatology vol. 41,4 (2011): 358-63. doi: https://doi.org/10.1111/j.1872-034X.2011.00779.x
Miura R, Tanaka A, Takikawa H. Urinary bile acid sulfate levels in patients with primary biliary cirrhosis. Hepatol Res. 2011 Apr;41(4):358-63. doi: 10.1111/j.1872-034X.2011.00779.x. Epub 2011 Feb 23. PMID: 21348908.
Copy Download .nbib Format: NLM
Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis.

Clinical and translational gastroenterology

Sclair SN, Little E, Levy C.
PMID: 26312413
Clin Transl Gastroenterol. 2015 Aug 27;6:e109. doi: 10.1038/ctg.2015.33.

Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are chronic, cholestatic diseases of the liver with common clinical manifestations. Early diagnosis and treatment of PBC slows progression and decreases the need for transplant. However, one-third of patients will...

Cite
Sclair SN, Little E, Levy C. Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clin Transl Gastroenterol. 2015;6:e109doi: 10.1038/ctg.2015.33.
Sclair, S. N., Little, E., & Levy, C. (2015). Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinical and translational gastroenterology, 6e109. https://doi.org/10.1038/ctg.2015.33
Sclair, Seth N, et al. "Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis." Clinical and translational gastroenterology vol. 6 (2015): e109. doi: https://doi.org/10.1038/ctg.2015.33
Sclair SN, Little E, Levy C. Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clin Transl Gastroenterol. 2015 Aug 27;6:e109. doi: 10.1038/ctg.2015.33. PMID: 26312413; PMCID: PMC4816277.
Copy Download .nbib Format: NLM
Analysis of mutations of .

Experimental and therapeutic medicine

Yang XF, Liu GS, Li MX.
PMID: 26668642
Exp Ther Med. 2015 Dec;10(6):2361-2365. doi: 10.3892/etm.2015.2800. Epub 2015 Oct 14.

The aim of this study was to investigate mutations of multidrug resistance 3 (MDR3) exons 9 and 23 in infants with parenteral nutrition-associated cholestasis (PNAC). A total of 41 infants with PNAC were enrolled in the study. Genomic DNA...

Cite
Yang XF, Liu GS, Li MX. Analysis of mutations of . Exp Ther Med. 2015;10(6):2361-2365doi: 10.3892/etm.2015.2800.
Yang, X. F., Liu, G. S., & Li, M. X. (2015). Analysis of mutations of . Experimental and therapeutic medicine, 10(6), 2361-2365. https://doi.org/10.3892/etm.2015.2800
Yang, Xiu-Fang, et al. "Analysis of mutations of ." Experimental and therapeutic medicine vol. 10,6 (2015): 2361-2365. doi: https://doi.org/10.3892/etm.2015.2800
Yang XF, Liu GS, Li MX. Analysis of mutations of . Exp Ther Med. 2015 Dec;10(6):2361-2365. doi: 10.3892/etm.2015.2800. Epub 2015 Oct 14. PMID: 26668642; PMCID: PMC4665683.
Copy Download .nbib Format: NLM
Omega-3 Polyunsaturated Fatty Acid for Cholestasis due to Bile Duct Paucity.

Pediatric gastroenterology, hepatology & nutrition

Bae SH, Park HS, Han HS, Yun IJ.
PMID: 25061589
Pediatr Gastroenterol Hepatol Nutr. 2014 Jun;17(2):121-4. doi: 10.5223/pghn.2014.17.2.121. Epub 2014 Jun 30.

Omega (ω)-3 polyunsaturated fatty acids appear to be effective in preventing and treating parenteral nutrition-associated liver disease, and several mechanisms were proposed for this observation. An 8-week-old male infant with cholestasis and acholic stool was diagnosed non-syndromic intrahepatic interlobular...

Cite
Bae SH, Park HS, Han HS, et al. Omega-3 Polyunsaturated Fatty Acid for Cholestasis due to Bile Duct Paucity. Pediatr Gastroenterol Hepatol Nutr. 2014;17(2):121-4doi: 10.5223/pghn.2014.17.2.121.
Bae, S. H., Park, H. S., Han, H. S., & Yun, I. J. (2014). Omega-3 Polyunsaturated Fatty Acid for Cholestasis due to Bile Duct Paucity. Pediatric gastroenterology, hepatology & nutrition, 17(2), 121-4. https://doi.org/10.5223/pghn.2014.17.2.121
Bae, Sun Hwan, et al. "Omega-3 Polyunsaturated Fatty Acid for Cholestasis due to Bile Duct Paucity." Pediatric gastroenterology, hepatology & nutrition vol. 17,2 (2014): 121-4. doi: https://doi.org/10.5223/pghn.2014.17.2.121
Bae SH, Park HS, Han HS, Yun IJ. Omega-3 Polyunsaturated Fatty Acid for Cholestasis due to Bile Duct Paucity. Pediatr Gastroenterol Hepatol Nutr. 2014 Jun;17(2):121-4. doi: 10.5223/pghn.2014.17.2.121. Epub 2014 Jun 30. PMID: 25061589; PMCID: PMC4107220.
Copy Download .nbib Format: NLM
Hepatopancreatobiliary manifestations of inflammatory bowel disease.

Clinical journal of gastroenterology

Nakamura K, Ito T, Kotoh K, Ihara E, Ogino H, Iwasa T, Tanaka Y, Iboshi Y, Takayanagi R.
PMID: 26181867
Clin J Gastroenterol. 2012 Feb;5(1):1-8. doi: 10.1007/s12328-011-0282-1. Epub 2012 Jan 06.

Inflammatory bowel disease (IBD) is frequently associated with extraintestinal manifestations such as hepatopancreatobiliary manifestations (HPBMs), which include primary sclerosing cholangitis (PSC), pancreatitis, and cholelithiasis. PSC is correlated with IBD, particularly ulcerative colitis (UC); 70-80% of PSC patients in Western...

Cite
Nakamura K, Ito T, Kotoh K, et al. Hepatopancreatobiliary manifestations of inflammatory bowel disease. Clin J Gastroenterol. 2012;5(1):1-8doi: 10.1007/s12328-011-0282-1.
Nakamura, K., Ito, T., Kotoh, K., Ihara, E., Ogino, H., Iwasa, T., Tanaka, Y., Iboshi, Y., & Takayanagi, R. (2012). Hepatopancreatobiliary manifestations of inflammatory bowel disease. Clinical journal of gastroenterology, 5(1), 1-8. https://doi.org/10.1007/s12328-011-0282-1
Nakamura, Kazuhiko, et al. "Hepatopancreatobiliary manifestations of inflammatory bowel disease." Clinical journal of gastroenterology vol. 5,1 (2012): 1-8. doi: https://doi.org/10.1007/s12328-011-0282-1
Nakamura K, Ito T, Kotoh K, Ihara E, Ogino H, Iwasa T, Tanaka Y, Iboshi Y, Takayanagi R. Hepatopancreatobiliary manifestations of inflammatory bowel disease. Clin J Gastroenterol. 2012 Feb;5(1):1-8. doi: 10.1007/s12328-011-0282-1. Epub 2012 Jan 06. PMID: 26181867.
Copy Download .nbib Format: NLM
Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review.

Beilstein journal of organic chemistry

Tonin F, Arends IWCE.
PMID: 29520309
Beilstein J Org Chem. 2018 Feb 20;14:470-483. doi: 10.3762/bjoc.14.33. eCollection 2018.

Ursodeoxycholic acid (UDCA) is a pharmaceutical ingredient widely used in clinics. As bile acid it solubilizes cholesterol gallstones and improves the liver function in case of cholestatic diseases. UDCA can be obtained from cholic acid (CA), which is the...

Cite
Tonin F, Arends IWCE. Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review. Beilstein J Org Chem. 2018;14:470-483doi: 10.3762/bjoc.14.33.
Tonin, F., & Arends, I. W. C. E. (2018). Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review. Beilstein journal of organic chemistry, 14470-483. https://doi.org/10.3762/bjoc.14.33
Tonin, Fabio, and Arends, Isabel W C E. "Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review." Beilstein journal of organic chemistry vol. 14 (2018): 470-483. doi: https://doi.org/10.3762/bjoc.14.33
Tonin F, Arends IWCE. Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review. Beilstein J Org Chem. 2018 Feb 20;14:470-483. doi: 10.3762/bjoc.14.33. eCollection 2018. PMID: 29520309; PMCID: PMC5827811.
Copy Download .nbib Format: NLM
Presentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to Treatment.

Pediatric gastroenterology, hepatology & nutrition

Boga S, Jain D, Schilsky ML.
PMID: 26473142
Pediatr Gastroenterol Hepatol Nutr. 2015 Sep;18(3):202-8. doi: 10.5223/pghn.2015.18.3.202. Epub 2015 Sep 25.

Progressive familial intrahepatic cholestasis type 3 (PFIC3) is an autosomal recessive disorder of cholestasis of hepatocellular origin, typically seen in infancy or childhood caused by a defect in the ABCB4 located on chromosome 7. Here we report on an...

Cite
Boga S, Jain D, Schilsky ML. Presentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to Treatment. Pediatr Gastroenterol Hepatol Nutr. 2015;18(3):202-8doi: 10.5223/pghn.2015.18.3.202.
Boga, S., Jain, D., & Schilsky, M. L. (2015). Presentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to Treatment. Pediatric gastroenterology, hepatology & nutrition, 18(3), 202-8. https://doi.org/10.5223/pghn.2015.18.3.202
Boga, Salih, et al. "Presentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to Treatment." Pediatric gastroenterology, hepatology & nutrition vol. 18,3 (2015): 202-8. doi: https://doi.org/10.5223/pghn.2015.18.3.202
Boga S, Jain D, Schilsky ML. Presentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to Treatment. Pediatr Gastroenterol Hepatol Nutr. 2015 Sep;18(3):202-8. doi: 10.5223/pghn.2015.18.3.202. Epub 2015 Sep 25. PMID: 26473142; PMCID: PMC4600706.
Copy Download .nbib Format: NLM
Novel strategies and therapeutic options for the management of primary biliary cholangitis.

Therapeutic advances in gastroenterology

Khanna A, Jones DE.
PMID: 29051789
Therap Adv Gastroenterol. 2017 Oct;10(10):791-803. doi: 10.1177/1756283X17728669. Epub 2017 Sep 07.

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease. It has a varied course of progression ranging from being completely asymptomatic to aggressive disease leading to cirrhosis and resulting in liver transplantation. In addition, symptoms can be debilitating...

Cite
Khanna A, Jones DE. Novel strategies and therapeutic options for the management of primary biliary cholangitis. Therap Adv Gastroenterol. 2017;10(10):791-803doi: 10.1177/1756283X17728669.
Khanna, A., & Jones, D. E. (2017). Novel strategies and therapeutic options for the management of primary biliary cholangitis. Therapeutic advances in gastroenterology, 10(10), 791-803. https://doi.org/10.1177/1756283X17728669
Khanna, Amardeep, and Jones, David E. "Novel strategies and therapeutic options for the management of primary biliary cholangitis." Therapeutic advances in gastroenterology vol. 10,10 (2017): 791-803. doi: https://doi.org/10.1177/1756283X17728669
Khanna A, Jones DE. Novel strategies and therapeutic options for the management of primary biliary cholangitis. Therap Adv Gastroenterol. 2017 Oct;10(10):791-803. doi: 10.1177/1756283X17728669. Epub 2017 Sep 07. PMID: 29051789; PMCID: PMC5638183.
Copy Download .nbib Format: NLM
Risk and Surveillance of Cancers in Primary Biliary Tract Disease.

Gastroenterology research and practice

Hrad V, Abebe Y, Ali SH, Velgersdyk J, Al Hallak M, Imam M.
PMID: 27413366
Gastroenterol Res Pract. 2016;2016:3432640. doi: 10.1155/2016/3432640. Epub 2016 Jun 19.

Primary biliary diseases have been associated in several studies with various malignancies. Understanding the risk and optimizing surveillance strategy of these malignancies in this specific subset of patients are an important facet of clinical care. For instance, primary sclerosing...

Cite
Hrad V, Abebe Y, Ali SH, et al. Risk and Surveillance of Cancers in Primary Biliary Tract Disease. Gastroenterol Res Pract. 2016;2016:3432640doi: 10.1155/2016/3432640.
Hrad, V., Abebe, Y., Ali, S. H., Velgersdyk, J., Al Hallak, M., & Imam, M. (2016). Risk and Surveillance of Cancers in Primary Biliary Tract Disease. Gastroenterology research and practice, 20163432640. https://doi.org/10.1155/2016/3432640
Hrad, Valery, et al. "Risk and Surveillance of Cancers in Primary Biliary Tract Disease." Gastroenterology research and practice vol. 2016 (2016): 3432640. doi: https://doi.org/10.1155/2016/3432640
Hrad V, Abebe Y, Ali SH, Velgersdyk J, Al Hallak M, Imam M. Risk and Surveillance of Cancers in Primary Biliary Tract Disease. Gastroenterol Res Pract. 2016;2016:3432640. doi: 10.1155/2016/3432640. Epub 2016 Jun 19. PMID: 27413366; PMCID: PMC4930812.
Copy Download .nbib Format: NLM
An Update on Treatment of Drug-Induced Liver Injury.

Journal of clinical and translational hepatology

Giordano C, Rivas J, Zervos X.
PMID: 26356645
J Clin Transl Hepatol. 2014 Jun;2(2):74-9. doi: 10.14218/JCTH.2014.00005. Epub 2014 Jun 15.

Drug-induced liver injury (DILI) has been linked to more than 1,000 medications and remains the most common cause of acute liver failure in the United States. Here, we review the most current literature regarding treatment and make recommendations for...

Cite
Giordano C, Rivas J, Zervos X. An Update on Treatment of Drug-Induced Liver Injury. J Clin Transl Hepatol. 2014;2(2):74-9doi: 10.14218/JCTH.2014.00005.
Giordano, C., Rivas, J., & Zervos, X. (2014). An Update on Treatment of Drug-Induced Liver Injury. Journal of clinical and translational hepatology, 2(2), 74-9. https://doi.org/10.14218/JCTH.2014.00005
Giordano, Christin, et al. "An Update on Treatment of Drug-Induced Liver Injury." Journal of clinical and translational hepatology vol. 2,2 (2014): 74-9. doi: https://doi.org/10.14218/JCTH.2014.00005
Giordano C, Rivas J, Zervos X. An Update on Treatment of Drug-Induced Liver Injury. J Clin Transl Hepatol. 2014 Jun;2(2):74-9. doi: 10.14218/JCTH.2014.00005. Epub 2014 Jun 15. PMID: 26356645; PMCID: PMC4521262.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 558 entries